New projections show the global cannabis testing services market on track to more than double within the decade, growing from $1.51 billion in 2024 to $3.79 billion by 2030.

(Photo credit: Brock University).

The upward trajectory, driven by a 16.58% CAGR (compound annual growth rate) reflects the continued legalization of marijuana worldwide and a tightening regulatory environment that requires rigorous product testing before anything reaches consumers, notes the report.

The newly released market analysis outlines how formalization of medical and adult-use markets is directly fueling demand for laboratory services that verify potency, purity, and safety. As more countries and U.S. states transition into regulated systems, cannabis manufacturers and cultivators are required to test for cannabinoids, terpenes, pesticides, heavy metals, microbial contaminants, residual solvents, and other quality markers. That shift has created a sustained need for large-scale testing capacity. The report notes that states collected $4.4 billion in adult-use marijuana tax revenue in 2024, underscoring the growth of regulated, test-dependent distribution channels.

Alongside this demand surge, the report highlights one of the industry’s biggest obstacles: inconsistent rules from one region to the next. Companies operating in multiple jurisdictions face a patchwork of standards that often requires separate testing protocols, accreditation processes, and equipment calibrations. For laboratories, this fragmentation creates continual compliance challenges and raises operational costs, slowing the pace of harmonization even as markets expand.

Despite those hurdles, the industry is undergoing a technological shift that is reshaping how cannabis testing labs operate. Automation and high-throughput systems—such as robotic sample handling and advanced analytical instruments—are becoming central to lab workflows, cutting turnaround times while reducing human error. Broader manufacturing trends are accelerating this transition; a recent industry survey found that nearly one-third of professionals planned to acquire new lab testing equipment or software in 2025, signaling widespread adoption of automated platforms.

North America continues to represent the largest regional market, but growth is spreading across Europe, Asia-Pacific, and emerging legal markets in South America and the Middle East. Cannabis drug manufacturers represent the fastest-growing end-use segment, followed closely by cultivators that require testing to remain compliant as product lines diversify.

Major companies expanding their footprint in the sector include Eurofins Scientific, Saskatoon Research Council, PHARMLABS, Steep Hill Labs, CW Analytics, Greenleaf Corp., Praxis Labs, and SGS Canada. The report notes that the industry’s competitive landscape is likely to intensify as more operators integrate automation and scale their service offerings.

With legalization trends accelerating and global regulations continuing to mature, cannabis testing services are expected to remain one of the most essential—and fastest-expanding—components of the marijuana supply chain through 2030.